Evidence-based medicine in health care reform

Otolaryngology - Head and Neck Surgery

Volumn 145, Issue 4, 2011, Pages 526-529

  Hughes, Gordon B ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

Evidence based medicine; Health care reform

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; MEDICAL RESEARCH; OBSERVATIONAL STUDY; SYSTEMATIC REVIEW (TOPIC); COMPARATIVE EFFECTIVENESS; ECONOMICS; HUMAN; STANDARD; STATISTICS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; ELECTRONIC HEALTH RECORDS; EVIDENCE-BASED MEDICINE; HEALTH CARE REFORM; HUMANS; PATIENT PROTECTION AND AFFORDABLE CARE ACT; UNITED STATES;

EID: 84856389421     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599811419458     Document Type: Article

References (25)

1. The Staff of the Washington Post. Landmark: The Inside Story of America's New Health-Care Law and What It Means for Us All. New York: Public Affairs, Perseus Books Group; 2010.
2. Federal Coordinating Council for Comparative Effectiveness Research. Recovery act allocates $1.1 billion for comparative effectiveness research. 2008. http://www.hhs.gov/recovery/programs/os/cerbios.html. Accessed April 6, 2011.
3. US Department of Health and Human Services. NIH challenge grants in health and science research. 2009. http://grants.nih.gov/grants/funding/ challenge-award/. Accessed August 28, 2010.
4. Center for Evidence-Based Medicine. http://www.cebm.net/. Accessed June 12, 2009.
5. Sackett DL, Rosenberg WM, Gray JH, et al. Evidence-based medicine: What it is and what it isn't. BMJ. 1996;312:71-72.
6. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490-1494.
7. Guyatt GH, Oxman AD, Vist G, et al, for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. (Pubitemid 351632017)
8. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, for the GRADE Working Group. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336(7651):995-998. (Pubitemid 351656090)
9. Schünemann HJ, Oxman AD, Brozek J, et al, for the GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106-1110. (Pubitemid 351731739)
10. Guyatt GH, Oxman AD, Kunz R, et al, for the GRADE Working Group. Rating quality of evidence and strength of recommendations: incorporating considerations of resources use into grading recommendations. BMJ. 2008;336(7654):1170-1173. (Pubitemid 351809277)
11. Guyatt GH, Oxman AD, Kunz R, et al, for the GRADE Working Group. Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ. 2008;336(7652):1049-1051.
12. Jaeschke R, Guyatt GH, Dellinger P, et al, for the GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
13. Kaitin KI, ed. Tufts Center for the Study of Drug Development Impact Report. Boston: Tufts Center for the Study of Drug Development; 2010.
14. Miller G. Is Pharma running out of brainy ideas? Science. 2010;329:502-504.
15. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-185. (Pubitemid 36279392)
16. DiMasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther. 2001;69(5):286-296. (Pubitemid 32477069)
17. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Drug Inf J. 2004;38:211-223.
18. Glickman SW, McHutchinson JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816-823.
19. Pasquali SK, Burstein DS, Benjamin DK Jr, et al. Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics. 2010;126(3):e687-e693.
20. Harris G. Report Assails F.D.A. Oversight of Clinical Trials. New York Times. September 28, 2007.
21. Miller HI. Anti-drug fear factor trumps facts. FDA found no danger but liberals are addicted to hype. The Washington Times. August 24, 2010.
22. Hochman M, McCormick D. Characteristics of published comparative effectiveness studies of medications. JAMA. 2010;303(10):951-958.
23. Ellenberg S, Kaitin K, Goldhammer A, Siegel J, Temple R. Why do so many investigational drugs ultimately fail? Presented at: Society for Clinical Trials; May 17, 2010; Baltimore, MD.
24. Lusk RP. The "meaningful use" of HER. American Academy of Otolaryngology-Head and Neck Surgery Bulletin. September 2010:23-24.
25. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Updated March 2011. http://www.cochrane-handbook.org/. Accessed April 5, 2011.